1. Induction Chemotherapy for Patients With High-Risk or Secondary AML

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Standard for Intensive Induction Therapy: 7+3

4. Considerations for Older Patients

5. Typical Results With 7+3

6. Challenges With Intensive Induction Therapy

7. Dose Reduction to 5+2

8. Hypomethylating Agents

9. Low-Dose (20 mg BID SQ) Cytarabine

10. Clofarabine

11. Alternative Formulation: CPX-351

12. Phase 2 Study of CPX-351

13. Phase 3 Study of CPX-351

14. Concluding Remarks

15. Abbreviations

16. Abbreviations (cont)